AstraNova can help define the assays, biomarkers, and counter-screens needed to understand whether your target is tractable.
The human kinome comprises over 500 kinase domains, and selectivity across this target class is a defining challenge in kinase drug discovery. Our kinase pharmacology platform delivers rigorous selectivity profiling, resistance mutation characterization, and isoform-selective compound profiling.
GPCRs represent the largest druggable target class, and their pharmacological complexity demands specialized expertise. AstraNova maintains one of the broadest GPCR assay libraries in the CRO sector, enabling receptor subtype selectivity profiling, biased agonism characterization, and GPCR interactome analysis.
Ion channel pharmacology requires electrophysiology, flux-based assays, and fluorescence platforms that collectively characterize both channel gating modulation and state-dependent pharmacology. Our platform covers voltage-gated, ligand-gated, and mechanosensitive channel families.
Histone modifying enzymes, chromatin readers, and DNA methyltransferases represent validated targets across oncology, CNS, and inflammatory diseases. Our epigenetics platform covers the full epigenome-relevant target set with biochemical and cellular readouts.
Transcription factor-directed pharmacology for nuclear receptors — including ligand-binding domain characterization, coactivator displacement, and transactivation assays — supports drug programs targeting hormonal, metabolic, and inflammatory pathways.
Targeting the intracellular PPI space requires specialized biophysical and cell-based platforms. AstraNova's PPI platform spans SPR binding kinetics through proximity-based cellular assays, supporting inhibitor discovery and PROTAC ternary complex evaluation.
Bring us the program question, constraints, and next decision point. We will map the right assays, controls, timeline, and reporting package before the first plate is run.
